Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WIN-Partners CoTSE:3183 -0.39%62 EV-to-EBITDA is 6.11 as of Aug. 29, 2026, which is 1% above its 10-year median of 6.02. GuruFocus rates TSE:3183 with a GF Score™ of 62/100 and a GF Value™ of 円1,501.60 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 99 Medical Distribution companies, WIN-Partners Co ranks better than 67.68% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, WIN-Partners Co's enterprise value is 円19,650 Mil.
WIN-Partners Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円3,216 Mil. Therefore, WIN-Partners Co's EV-to-EBITDA for today is 6.11.
The historical rank and industry rank for WIN-Partners Co's EV-to-EBITDA or its related term are showing as below:
TSE:3183'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.17 Med: 6.02 Max: 13.62
Current: 6.1
During the past 13 years, the highest EV-to-EBITDA of WIN-Partners Co was 13.62. The lowest was 2.17. And the median was 6.02.
TSE:3183's EV-to-EBITDA is ranked better than 67.68% of 99
companies
in the Medical Distribution industry
Industry Median: 8.49
vs TSE:3183: 6.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
WIN-Partners Co (TSE:3183) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
WIN-Partners Co's PE Ratio (TTM) for today is calculated as:
WIN-Partners Co's share price for today is 円1268.00.
WIN-Partners Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円74.693.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for WIN-Partners Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3183 vs MCK, COR, CAH: EV-to-EBITDA Comparison
For the Medical Distribution subindustry, WIN-Partners Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WIN-Partners Co EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, WIN-Partners Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where WIN-Partners Co's EV-to-EBITDA falls into.
WIN-Partners Co's current Enterprise Value is 円19,650 Mil.
WIN-Partners Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3,216 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WIN-Partners Co (TSE:3183) has a EV-to-EBITDA of 6.11 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on WIN-Partners Co. This is near median its historical median of 6.02. Over the past decade, WIN-Partners Co's EV-to-EBITDA has ranged from 2.17 to 13.62. According to the industry distribution chart, WIN-Partners Co ranks #32 out of 99 companies in the Medical Distribution industry, placing it in the top 32.3%.
Is WIN-Partners Co's EV-to-EBITDA too high?
WIN-Partners Co's current EV-to-EBITDA of 6.11 is near median its 10-year median of 6.02. Over the past 10 years, this metric has ranged from a low of 2.17 to a high of 13.62. The Medical Distribution industry median EV-to-EBITDA is 8.49. WIN-Partners Co's value of 6.11 is 28% below this industry median. Based on the distribution chart, WIN-Partners Co ranks #32 out of 99 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, WIN-Partners Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WIN-Partners Co's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, WIN-Partners Co ranks #32 out of 99 companies for EV-to-EBITDA. This puts WIN-Partners Co in the upper half of its industry. The industry median EV-to-EBITDA is 8.49. WIN-Partners Co's value of 6.11 is 28% below this benchmark. Historically, WIN-Partners Co's own EV-to-EBITDA has ranged from 2.17 to 13.62 over the past decade. While the company's 10-year median is 6.02 vs. the industry median of 8.49, WIN-Partners Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.49, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WIN-Partners Co's current EV-to-EBITDA of 6.11 is 28% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on WIN-Partners Co. For the Medical Distribution industry, the median EV-to-EBITDA is 8.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WIN-Partners Co's current EV-to-EBITDA is 6.11, which is near median its own 10-year median of 6.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WIN-Partners Co stock overvalued right now?
Based on GuruFocus' analysis, WIN-Partners Co (TSE:3183) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,501.60, compared to a current price of 円1,268.00 — trading 15.6% below its estimated fair value. The current EV-to-EBITDA is 6.11, which is near median its 10-year median of 6.02 and 28% below the Medical Distribution industry median of 8.49. WIN-Partners Co's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For WIN-Partners Co (TSE:3183), the current EV-to-EBITDA is 6.11 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WIN-Partners Co (TSE:3183) Overvalued in 2026?
Based on GuruFocus' analysis, WIN-Partners Co stock appears to be undervalued.
The current stock price of 円1,268.00 is trading 15.6% below its estimated GF Value™ of 円1,501.60.
GuruFocus considers WIN-Partners Co to be Modestly Undervalued.
Key valuation signals for TSE:3183:
EV-to-EBITDA: 6.11 (near median its 10-year median of 6.02)
GF Value™: 円1,501.60 vs. price of 円1,268.00 (15.6% below fair value)
Industry Position: 28% below the Medical Distribution median (#32 of 99)
No single metric tells the full story. See the TSE:3183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WIN-Partners Co Ltd is engaged in the healthcare sector. The company provides medical devices to Japan's medical institutions. Its products offerings are Cardiovascular device, Insulin Pump, X-ray Angio System, Carotid Artery Stent, Stent Graft, among others. The company operates only in one segment which is the medical equipment sales business.
62GF Score
Get the complete analysis for TSE:3183
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3183 has been successfully added to your 
